.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Updates in Systemic Therapy for Non-Metastatic Lung Cancer

EP. 1: Treatment of Early-Stage NSCLC: Current Standard of Care

October 26th 2020

EP. 2: Neoadjuvant Chemotherapy in Early-Stage NSCLC

October 26th 2020

EP. 3: Role of Postoperative Radiotherapy in Early Stage NSCLC

October 26th 2020

EP. 4: Phase 3 ADAURA Study: EGFR-Mutated NSCLC

October 26th 2020

EP. 5: Patient Selection: Adjuvant Therapy and Testing for ES NSCLC

October 26th 2020

EP. 6: Role of Neoadjuvant I/O in ES NSCLC

October 26th 2020

EP. 7: Key Trials in Neoadjuvant I/O for ES NSCLC

October 26th 2020

EP. 8: Neoadjuvant I/O for ES NSCLC: Key Trials from ESMO 2020

October 26th 2020

EP. 9: Future of Neoadjuvant I/O in ES NSCLC

October 26th 2020

EP. 10: PACIFIC Trial in Stage 3 NSCLC

October 26th 2020

EP. 11: Considering PD-L1 and EGFR Status With I/O in Stage 3 NSCLC

October 26th 2020

EP. 12: Risk of Pneumonitis Post-Chemoradiation in Stage 3 NSCLC

October 26th 2020

EP. 13: Takeaways on Treatment of Early-Stage NSCLC

October 26th 2020